Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Leukemia|September 20, 2022
Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapyPaolo Strati, Andrew P Jallouk, Ryan Sun, et al.
Blood Cancer Journal|May 3, 2023
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patientsOren Pasvolsky, Denái R Milton, Mikael Rauf, et al.
Transplantation and Cellular Therapy|January 2, 2025
Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell TransplantationOren Pasvolsky, Curtis Marcoux, Zhongya Wang, et al.
Leukemia & Lymphoma|January 29, 2026
Lenalidomide maintenance after delayed or salvage autologous stem cell transplantationAsad A Haider, Curtis Marcoux, Denái R Milton, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 27, 2026
Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide MaintenanceOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
British Journal of Haematology|March 30, 2025
Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant responseOren Pasvolsky, Muhammad Bilal Abid, Denái R Milton, et al.
Transplantation and Cellular Therapy|July 30, 2021
Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical TrialRohtesh S Mehta, Roland Bassett, Julianne Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell LymphomaKhushali Jhaveri, Ram Thapa, Dalia Ercan, et al.
Blood Advances|August 23, 2023
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbiditiesUday R Popat, Oren Pasvolsky, Roland Bassett, et al.
Haematologica|May 6, 2021
Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysisYago Nieto, Stephen Gruschkus, Benigno C Valdez, et al.
Pageof 9